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as shown in the table. Multivariate logistic regression analysis, DM was independent
predictor of intra-stent thrombi on OCT (OR 14.031, 95% CI 2.556-77.033, p0.002),
adjusting ARU, PRU and major risk factors, but ARU, PRU and aspirin / clopidogrel
resistance were not related to intra-stent thrombi on OCT.
Conclusions: This OCT study demonstrated that ARU, PRU and aspirin / clopidogrel
resistance were not related to intra-stent thrombi on OCT.
All Patients (n313) p DM (n94) P
AR (	) 3 (8.6%) 0.288 2 (11.1%) 1.000
AR () 12 (4.4%) 8 (11.1%)
CR (	) 5 (3.0%) 0.107 5 (8.8%) 0.466
CR () 10 (7.0%) 5 (13.5%)
HTN (n184) p Age>75 (n18) p
0 0.341 0 1.000
8 (4.8%) 1 (7.1%)
5 (4.6%) 0.823 1 (7.7%) 1.000
3 (3.9%) 0
OCT-D>6month (n170) p
3 (11.1%) 0.408
9 (6.3%)
3 (3.9%) 0.234
9 (9.2%)
AR : Aspirin resistance (ARU550), CR ; Clopidogrel resistance (PRU250), DM ; Diabetes
mellitus, HTN ; Hypertension, OCD-D ; OCT follow-up duration, p ; p-value
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Background: Although high on-treatment platelet reactivity (HoTPR) predicts future
ischemic events after percutaneous coronary intervention (PCI), the clinical applicability
of platelet function testing remain unclear. This study aims to evaluate the impact of
platelet function testing results on the managing physician’s response to escalate
antiplatelet therapy after PCI.
Methods: The study included 465 consecutive patients undergoing PCI who were on5
days of maintenance clopidogrel therapy. We performed platelet function testing with the
Verify Now P2Y12 (Accumetrics) assay before the PCI. The result of this assay was made
known to the managing physician after PCI. HoTPR was defined as230 P2Y12 reaction
units (PRU). Antiplatelet therapy at baseline and at hospital discharge post-PCI was
recorded. We also evaluated the 30-day major adverse clinical events (MACE: all-cause
mortality, myocardial infarction, and target vessel revascularization) in this population.
Results: The mean age of the study population was 63 years; 73% were male and 22%
were African-American. HoTPR was present in 143 patients (30.8%). Of these, only
21(14.7%) were managed with an escalation of antiplatelet therapy (increased clopidogrel
dose or switched to prasugrel). Of the remaining 322 patients with appropriate platelet
inhibition of230PRU, 55 (17.1%) received more intensive antiplatelet therapy. Patients
more likely to receive intensified antiplatelet therapy were those with a history of coronary
artery bypass grafting (p0.03), diabetes mellitus (p0.03), and dialysis (p0.04), as
well as those presenting with myocardial infarction (p0.014), receiving vein-graft PCI
and treatment to a complex (ACC/AHA type C) lesion. At 30 days, 4 MACE events
occurred. The group with HoTPR who received intensified antiplatelet therapy had the
highest proportion of events (4.7% vs 2.2%, p0.04).
Conclusions: The results of platelet function testing do not significantly impact decisions
to alter amtiplatelet therapy post-PCI. Rather, baseline clinical and angiographic param-
eters were primary factors considered when intensifying antiplatelet therapy.
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Background: ADP-specific platelet function assays were shown to predict thrombotic
events, and might be helpful to select candidates for more potent antiplatelet therapy. We
aimed to determine the efficacy and safety of giving intensified antiplatelet therapy on the
basis of platelet reactivity testing for patients undergoing percutaneous coronary inter-
vention (PCI).
Methods: Electronic databases were searched to find prospective, randomized trials that
reported the clinical impact of using an intensified antiplatelet protocol (repeated loading
or elevated maintenance doses of clopidogrel, prasugrel or glycoprotein IIb/IIIa inhibitor)
on the basis of ADP-specific platelet reactivity testing (using VerifyNow, Multiplate,
VASP or light transmission aggregometry) compared to standard-dose clopidogrel.
Evaluated efficacy measures included cardiovascular death, non-fatal myocardial infarc-
tion and definite/probable stent thrombosis (ST), while major bleeding events were
recorded as safety endpoint.
Results: Between 2008 and 2011, 10 clinical trials comprising 4,213 randomized patients
were identified. Compared to standard antiplatelet therapy, the intensified protocol was
associated with a significant reduction in cardiovascular mortality, ST and myocardial
infarction (p0.01 for all). There was no difference in the rate of major bleeding events
between intensified and standard groups (P0.44). Although the observed effects
regarding mortality, ST and bleeding were not heterogeneous, meta-regression analysis
revealed that the net clinical benefit of the more potent antiplatelet strategy in patients with
HPR significantly depended on the risk of ST of the control group using standard-dose
clopidogrel (p0.023).
Conclusions: Intensifying antiplatelet therapy on the basis of platelet reactivity testing
might reduce cardiovascular mortality and ST after PCI, without increasing major
bleeding complications. However, the net benefit of giving more potent agents based on
platelet function testing depends on the risk of ST with standard-dose clopidogrel.
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Background: The potential negative metabolic interaction between proton pump
inhibitors (PPI) and clopidogrel is of particular concern. We have hypothesized that
doubling the maintenance dose (MD) of clopidogrel (150mg, double) was less effective
than switching to prasugrel 10mg MD (switch) to attenuate this potential negative
interaction.
Methods: In a prospective randomized placebo-controlled double blind study, we
assigned 82 stable coronary artery disease patients treated with 75 mg clopidogrel MD
dose and aspirin to receive lanzoprazole (30mg/day) or placebo in addition to either
clopidogrel double MD (150 mg/jour) or standard prasugrel MD (10 mg/jour). The
primary endpoint was the relative change in residual platelet reactivity (RPA, assessed by
light transmission aggregometry, 20Mol ADP) over the 14 days study period [(RPA-
baseline-RPA14day)/RPAbaseline]. All the measures were performed 4 hours after drug
intake. Exclusion criteria were instability, contraindication to prasugrel and a mandatory
use of PPI.
Results: Baseline characteristics were balanced between the 4 groups. The effect of a
double clopidogrel MD on RPA was significantly blunted by the co-administration of
lansoprazole (-53.648.6% versus 0.853.7% without and with lansoprazole, respec-
tively, p0.001) whereas 10 mg of prasugrel MD dramatically reduced RPA irrespective
of lanzoprazole co-administration (-81.824.8% versus -72.932.9%, without and with
lanzoprazole, respectively, pNS). In patients receiving double clopidogrel MD and
lansoprazole, RPA was not significantly different from that of clopidogrel 75mg MD
alone. These findings were consistent irrespective of the platelet function test used to
assess RPA. PPI use was the only parameter with a significant interaction with RPA
among clopidogrel groups. CYP2C19 metabolizer status displayed non-significant inter-
action with RPA irrespective of the thienopyridine strategy.
Conclusions: The effect of a double clopidogrel MD on platelet inhibition is significantly
attenuated by the co-administration of lansoprazole as opposed to prasugrel 10mg.
TUESDAY, OCTOBER 23, 8:00 AM–10:00 AM www.jacc.tctabstracts2012.com
B218 JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Antithrombin and Antiplatelet Agents
P
O
ST
E
R
S
